Security
Bioxytran, Inc. Common Stock · BIXT
BIXTOTCCommon stockCurrentCIK 1445815Updated Oct 6, 2026
Name history
U.S. RARE EARTH MINERALS, INC. · through Oct 30, 2018U.S. RARE EARTH MINERALS, INC · through Oct 3, 2018U.S. Natural Nutrients & Minerals, Inc. · through Apr 14, 2011AMERICA'S DRIVING RANGES, INC. · through Oct 29, 2009
BIXT price & chart
Loading TradingView…
OTC:BIXT on TradingView ↗About the company
Bioxytran, Inc. (“we”, “us”, or the “Company”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia (a lack of oxygen to tissues) in humans. Hypoxia needs to be addressed quickly, otherwise it results in necrosis, the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, a hypoxia platform technology with code-name BXT-25, is planned to be an Acellular Oxygen Carrier (“AOC”) consisting of bovine hemoglobin stabilized with a co-polymer. BXT-25’s intended application includes the treatment of hypoxic conditions in the brain resulting from stroke. We believe that our approach is novel when applied to hypoxic conditions in humans. Our drug development efforts are guided by specialists who work on co-polymer chemistry and other disciplines. We intend to supplement our efforts with input from a scientific and medical advisory board whose members include leading physicians.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Other Events
Items 8.01, 9.01
10-Q filing
10-K filing
NT 10-K filing
Show 5 more recent filings
Unregistered Sales of Equity Securities · Other Events
Items 3.02, 8.01, 9.01
Material Modification to Rights of Security Holders · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.02, 5.03, 9.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 156,294Source | 159,008Source | 333,393Source | 147,501Source | 128,553Source | 615,253Source | 136,052Source | 125,540Source | 658,552Source | 138,694Source | 139,382Source | 370,936Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 14,499Source | 34,672Source | 177,384Source | 3,144Source | 13,522Source | 463,047Source | 4,348Source | 10,024Source | 513,465Source | 5,154Source | 26,086Source | 295,401Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,060,937Source | 1,243,578Source | 5,274,697Source | 2,782,771Source | 1,228,509Source | 5,010,121Source | 2,844,089Source | 1,115,901Source | 3,249,894Source | 1,930,642Source | 3,244,238Source | 3,663,482Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 43,429Source | 28,894Source | 43,284Source | 43,429Source | — | 43,284Source | 43,398Source | — | 43,284Source | 43,158Source | — | — |
| Common Stock, Value, IssuedUSD | 88,992Source | 82,239Source | 114,695Source | 88,992Source | 177,416Source | 113,362Source | 88,882Source | 173,032Source | 108,148Source | 86,783Source | 144,642Source | 123,252Source |
| Additional Paid in CapitalUSD | 17,471,675Source | — | 18,633,881Source | 17,471,675Source | 16,376,479Source | 18,561,721Source | 17,434,486Source | 15,828,748Source | 18,301,472Source | 16,999,279Source | 13,085,715Source | 8,392,430Source |
| Retained Earnings (Accumulated Deficit)USD | -20,522,092Source | -18,298,861Source | -23,733,164Source | -20,239,366Source | -16,959,641Source | -23,113,235Source | -20,274,803Source | -16,297,931Source | -21,044,246Source | -18,921,168Source | -15,699,327Source | -11,217,600Source |
| Liabilities and EquityUSD | 156,294Source | 159,008Source | 333,393Source | 147,501Source | 128,553Source | 615,253Source | 136,052Source | 125,540Source | 658,552Source | 138,694Source | 139,382Source | 370,936Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,060,937Source | 1,243,578Source | 5,274,697Source | 2,782,771Source | 1,228,509Source | 5,010,121Source | 2,844,089Source | 1,115,901Source | 3,249,894Source | 1,930,642Source | 3,244,238Source | 3,663,482Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | -694,210Source | — | — | -694,210Source | — | — | -680,886Source | -590,628Source |
| Stockholders' Equity Attributable to Parent | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Additional Paid in Capital, Common Stock | — | —Source | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -282,726Source | -392,374Source | -619,929Source | 35,439Source | -2,068,989Source | -1,353,635Source | -2,123,077Source | -2,380,005Source | -4,562,783Source | -2,657,304Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | 8,416Source | — | — | — | — | — | — | 88,100Source | 178,382Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -238,610Source | -167,323Source | -526,455Source | -55,737Source | -775,375Source | -1,805,670Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -9,227Source | -15Source | -23,091Source | -28,195Source | -44,301Source | -32,247Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 200,970Source | 166,532Source | 1,054,306Source | 63,000Source | 550,361Source | 2,060,960Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 32,043Source | — | — | 164,447Source | 52,425Source | 104,850Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 1,290,015Source | 26,998Source | 197,376Source | 634,025Source | 176,451Source | — |
| Amortization of Intangible AssetsUSD | — | — | 4,236Source | 1,516Source | — | — | 2,108Source | 1,851Source | 11,544Source | 7,950Source | 8,285Source | 3,644Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 264,796Source | — | 106,759Source | 307,402Source | -73,136Source | -804,752Source | -216,701Source | 133,121Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 133,867Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 159,131Source | 158,071Source | 189,121Source | 94,529Source | 213,974Source | 143,770Source | 648,229Source | 1,167,502Source | 1,403,324Source | 933,742Source |
| InterestExpenseNonoperatingUSD | — | — | 36,522Source | 17,845Source | 36,126Source | 30,112Source | 35,729Source | 31,157Source | 134,314Source | 84,240Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -282,726Source | -392,374Source | -619,929Source | 35,439Source | -2,068,989Source | -1,353,635Source | -2,123,077Source | -2,366,681Source | -4,472,525Source | -2,463,932Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -13,324Source | -90,258Source | -193,372Source |
| Nonoperating Income (Expense)USD | — | — | 213,279Source | -46,170Source | 34,671Source | 259,516Source | -135,936Source | -838,493Source | -280,568Source | -156,937Source | -762,571Source | -523,192Source |
| Operating ExpensesUSD | — | — | 496,005Source | 346,204Source | 654,600Source | 224,077Source | 1,933,053Source | 515,142Source | 1,842,509Source | 2,223,068Source | 3,800,212Source | 2,134,112Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 145,701Source | — | 438,986Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | — | 253,008Source | — | — |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -496,005Source | -346,204Source | -654,600Source | -224,077Source | -1,933,053Source | -515,142Source | -1,842,509Source | -2,223,068Source | -3,800,212Source | -2,134,112Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -282,726Source | -392,374Source | -619,929Source | 35,439Source | -2,068,989Source | -1,353,635Source | -2,123,077Source | -2,380,005Source | -4,562,783Source | -2,657,304Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -13,324Source | -90,258Source | -193,372Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -282,726Source | -392,374Source | -619,929Source | 35,439Source | -2,068,989Source | -1,353,635Source | -2,123,077Source | -2,366,681Source | -4,472,525Source | -2,463,932Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | -0.01Source | 0Source | -0.02Source | -0.02Source | -0.02Source | -0.02Source | -0.03Source | -0.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | -0.01Source | 0Source | -0.02Source | -0.02Source | -0.02Source | -0.02Source | -0.03Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 88,992,242Source | 126,391,176Source | 114,355,933Source | 88,839,723Source | 112,283,387Source | 88,839,723Source | 91,843,409Source | 138,598,691Source | 133,973,352Source | 115,139,380Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 88,992,242Source | 126,391,176Source | 114,355,933Source | 88,839,723Source | 112,283,387Source | 88,839,723Source | 91,843,409Source | 138,598,691Source | 133,973,352Source | — |
| Interest Expense (non-operating)USD | — | — | 36,522Source | 17,845Source | 36,126Source | 30,112Source | 35,729Source | 31,157Source | 134,314Source | 84,240Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 4,236Source | 1,516Source | — | — | 2,108Source | 1,851Source | 11,544Source | 7,950Source | 8,285Source | 3,644Source |
| General and Administrative ExpenseUSD | — | — | 159,131Source | 158,071Source | 189,121Source | 94,529Source | 213,974Source | 143,770Source | 648,229Source | 1,167,502Source | 1,403,324Source | 933,742Source |
| Nonoperating Income (Expense)USD | — | — | 213,279Source | -46,170Source | 34,671Source | 259,516Source | -135,936Source | -838,493Source | -280,568Source | -156,937Source | -762,571Source | -523,192Source |
| Operating ExpensesUSD | — | — | 496,005Source | 346,204Source | 654,600Source | 224,077Source | 1,933,053Source | 515,142Source | 1,842,509Source | 2,223,068Source | 3,800,212Source | 2,134,112Source |
| Research and Development ExpenseUSD | — | — | — | 51,000Source | 255,479Source | 102,500Source | 225,479Source | 349,500Source | 454,000Source | 112,337Source | 1,149,209Source | 977,768Source |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-284415
- Offering price
- market-price
- Ticker
- BIXT
Filing attachments
ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 EXHIBIT 99.1 Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA - August 11, 2026 - Bioxytran, Inc. (OTCQB: BIXT), a clinical-…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Bioxytran, Inc. Completes $1.2 Million Private Placement Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA - March 20, 2026 - Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-02
EX-99.1 2 ex99-1.htm EX-99.1 EXHIBIT 99.1 Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 Randomized, Double-Blind, Placebo-Controlled Study Demonstrates 90% Day-5 Viral Clearance and Favorable Safety at Highest Dose compared to 20% placebo control BOSTON, MA - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced result…
Read attachment ↗ex99-1.htm · 8-K · 2026-02-17
Exhibit 99.1 Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR® Dietary Supplement Needham, MA - February 17, 2026 - Bioxytran, Inc. (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD (“Khoury Medical”), a co…
Read attachment ↗ex99-1.htm · 8-K · 2026-02-11
Exhibit 99.1 BIOXYTRAN REPORTS POSITIVE PHASE 2 RESULTS DEMONSTRATING RAPID VIRAL CLEARANCE WITH PROLECTIN-M Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001) BOSTON, MASSACHUSETTS - Feb 11, 2026 - Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute v…
Read attachment ↗ex107.htm · S-1/A · 2025-02-05
EX-FILING FEES 3 ex107.htm CALCULATION OF REGISTRATION FEE Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Proposed Maximum Proposed Maximum Aggregate Amount of Offering Offering …
Read attachment ↗